“I want to thank Doug for his many valued contributions to the company,” said
“I am fortunate to have been able to contribute to the maturation of Paratek from a clinical- to commercial-stage organization and bringing our important new anti-infective option to patients,” stated Mr. Pagán. “I am pleased to have been part of the success of the organization, and believe that, with the
The Company also announced that
About Paratek Pharmaceuticals, Inc.
Paratek has submitted a marketing authorization application of omadacycline in the
Under a research agreement with the
SEYSARA™ (sarecycline) is an
Recognizing the serious threat of bacterial infections, Paratek is dedicated to providing solutions that enable positive outcomes and lead to better patient stories.
For more information, visit www.ParatekPharma.com or follow @ParatekPharma on Twitter.
Forward Looking Statements
This press release contains forward-looking statements including statements related to our overall strategy, products, prospects and potential. All statements, other than statements of historical facts, included in this press release are forward-looking statements, and are identified by words such as “advancing,” “expect,” “look forward,” “anticipate,” “continue,” and other words and terms of similar meaning. These forward-looking statements are based upon our current expectations and involve substantial risks and uncertainties. We may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in our forward-looking statements and you should not place undue reliance on these forward-looking statements. Our actual results and the timing of events could differ materially from those included in such forward-looking statements as a result of these risks and uncertainties. These and other risk factors are discussed under “Risk Factors” and elsewhere in our Annual Report on Form 10-K for the year ended
CONTACT:
Investor and Media Relations: | ||
Ben Strain | ||
617-807-6688 | ||
ir@ParatekPharma.com |